OAC
SRPT icon

OMERS Administration Corp’s Sarepta Therapeutics SRPT Stock Holding History

OMERS Administration Corp’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$864K Buy
48,054
+3,900
+9% +$73.8K 0.01% 724
2026
Q1 		$961K Buy
44,154
+2,900
+7% +$56.1K 0.01% 665
2025
Q4 		$888K Buy
+41,254
New +$869K 0.01% 553

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

OMERS Administration Corp's SRPT Position: Q2 2026 in Review

OMERS Administration Corp increased its Sarepta Therapeutics (SRPT) stake by 8.8% in Q2 2026, buying an estimated $73.8K and bringing the position to 48,054 shares worth $864K. The position accounts for 0.01% of the portfolio, ranked #724.

OMERS Administration Corp first reported a position in SRPT in Q4 2025 and has held it in 3 quarters since. The position peaked at $961K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • OMERS Administration Corp held 48,054 shares of Sarepta Therapeutics worth $864K as of Q2 2026.
  • OMERS Administration Corp bought 3,900 Sarepta Therapeutics shares in Q2 2026, an estimated $73.8K.
  • Sarepta Therapeutics made up 0.01% of OMERS Administration Corp's portfolio in Q2 2026, its #724 holding.
  • OMERS Administration Corp first reported a position in Sarepta Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • OMERS Administration Corp's Sarepta Therapeutics position peaked at $961K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.